Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Brook Riggins, Chief Financial Officer of Thiogenesis Therapeutics, Corp., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A including, for greater certainty, all documents and information that are incorporated by ...
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Patrice Rioux, Chief Executive Officer of Thiogenesis Therapeutics, Corp., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A including, for greater certainty, all documents and information that are incorporated by ...
Date: April 29, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, RIGGINS, Brook, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonabl...
THIOGENESIS THERAPEUTICS, CORP. Managements Discussion and Analysis For the Year Ended December 31, 2023 (Expressed in Canadian Dollars) 2 OVERVIEW Thiogenesis Therapeutics, Corp., (TTI or the Company) (formerly: Rozdi...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
TTI Dec 31, 2023 draft 7 April 24, 2024-2 THIOGENESIS THERAPEUTICS, CORP. Consolidated Financial Statements For the Years Ended December 31, 2023 and December 31, 2022 (Expressed in Canadian Dollars) MNP LLP 1 Adelaide Street Eas...
Date: March 25, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, to...
Date: January 29, 2024 Jurisdictions: British Columbia, Ontario, Quebec
Amend Report of Exempt Distribution Form 45-106F1 Form 45-106F1 Report of Exempt Distribution ITEM 1 REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. 2023 12 20 (YYYY-MM-DD) ITEM 2 PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whet...
Date: December 20, 2023 Jurisdictions: Ontario
Create a report of distributions outside Canada Form 72-503F FORM 72-503F REPORT OF DISTRIBUTIONS OUTSIDE CANADA 1. Full name, address and telephone number of the Issuer. a) Full name of issuer Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) / Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) b) Head office address ...
Date: December 20, 2023 Jurisdictions: British Columbia, Ontario, Quebec
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...